Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mice were exposed for 8 h to continuous small-particle aerosols containing natural mouse alpha interferon (estimated dosage 100 U per mouse) or one of two concentrations of hybrid recombinant alpha interferon A/D bgl (estimated dosages of 100 and 10,000 U per mouse, respectively). On days 1, 3, 5, 7, and 9 after exposure to these interferons, three mice from each group were inoculated intranasally with 100 PFU of vesicular stomatitis virus. Control mice were exposed to aerosols of saline or inoculated intraperitoneally with either natural mouse alpha interferon (350 U) or one of two doses of hybrid recombinant alpha interferon A/D bgl (350 or 35,000 U) and challenged similarly. Of mice injected intraperitoneally, only those given 35,000 U of hybrid recombinant alpha interferon A/D bgl 24 h before virus challenge were protected from pulmonary infection, compared with the saline-treated control mice. Of mice given 100 U of either interferon by small-particle aerosol, only those exposed 24 h before inoculation of vesicular stomatitis virus had reduced pulmonary titers of the virus. However, of mice given ca. 10,000 U of hybrid recombinant alpha interferon A/D bgl by small-particle aerosol, all groups except those exposed 9 days before virus inoculation had significantly reduced lung virus titers.
 ...
PMID:Duration of effect of interferon aerosol prophylaxis of vesicular stomatitis virus infection in mice. 298 82

Earlier we reported that tunicamycin (TM) treatment of L cells in vitro significantly enhances the antiviral activity of interferon (IFN) against viruses (such as vesicular stomatitis, Sindbis, and herpes simplex) which bud from membranes. However, no such enhancement of the antiviral activity of IFN by TM was observed against encephalomyocarditis virus (EMCV) (nonbudding). We were interested to know whether TM would similarly enhance the antiviral activity of IFN and IFN inducers in vivo against Semliki Forest virus (SFV) and EMCV infections in mice. It was observed that TM alone (0.001 to 5.0 micrograms per mouse) did not protect mice against infections of SFV and EMCV; instead, TM-treated mice died with virus-specific paralytic symptoms earlier than untreated animals. The enhanced mortality in TM-treated and SFV- or EMCV-infected mice was associated with the concomitant increase in virus titer in brain tissue. IFN significantly protected mice against SFV and EMCV infections. The antiviral protection of mice by IFN against both the viruses was markedly inhibited by TM administration. IFN inducers (polyinosinic acid-polycytidylic acid, 6-MFA [a mixture of proteins, polysaccharides, and double-stranded DNA isolated from Aspergillus ochraceus ATCC 28706]) protected a significant number of mice against SFV infection. However, no such protection was observed in mice injected with a combination of TM and IFN inducer. These results indicate that TM treatment inhibits the antiviral action of IFN or IFN inducers in vivo.
 ...
PMID:Tunicamycin treatment inhibits the antiviral activity of interferon in mice. 619 Jul 59

Baculovirus, which is extensively utilized as an excellent tool for production of recombinant protein in insect cells, has recently emerged as a novel and attractive gene delivery vehicle for mammalian cells. In the present study, a pseudotype baculovirus (with the glycoprotein of vesicular stomatitis virus (VSV-G) on the envelope) was used as vector to construct recombinant baculovirus coexpressing GP5 and M protein of porcine reproductive and respiratory syndrome virus (PRRSV), under the transcriptional control of two independent cytomegalovirus immediate early (CMV-IE) enhancer/promoters. The resultant recombinant baculovirus (BV-G-5m6) efficiently expressed PRRSV GP5 and M protein in mammalian cells. Intramuscular injection of BV-G-5m6 with various doses (1 x 10(8), 1 x 10(9), and 1 x 10(10)PFU/mouse) induced the production of PRRSV-specific neutralizing antibodies and gamma interferon (IFN-gamma) under dose-dependent pattern. Furthermore, BV-G-5m6 performed better immunogenicity, even at low dose (10(8)PFU), than DNA construct (pCI-5m6) encoding the same antigens, as demonstrated by significantly enhanced neutralizing antibodies and IFN-gamma production. These results indicate that pseudotype baculovirus-mediated gene delivery can be utilized as an alternative strategy to develop new generation of vaccine against PRRSV infection.
 ...
PMID:Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. 1798 Apr 65

Toxoplasma gondii is a protozoan parasite causing toxoplasmosis to almost one-third of population all over the world. One of the most efficient ways to control this disease is immunization. However, so far, there is no effective vaccine available against this pathogen. Recently, a baculovirus pseudotype with vesicular stomatitis virus G protein (Bac-VSV-G) was found to efficiently transduce and express transgenes on mammalian cells, so it was considered as an excellent expressing vector. In this study, the value of Bac-VSV-G in delivering T. gondii antigen was investigated. T. gondii SAG1 gene was cloned into Bac-VSV-G, and recombinant baculovirus BV-G-SAG1 was obtained. Indirect immunofluorescence test showed BV-G-SAG1 was efficiently transduced and expressed in pig kidney cells. Then BALB/c mice were immunized with BV-G-SAG1 at different doses (1 x 10(8), 1 x 10(9), and 1 x 10(10)PFU/mouse) and challenged with T. gondii RH strain tachyzoites after immunization. The levels of specific T. gondii antibody, interferon (IFN)-gamma, IL-4, IL-10 expression and release, and the survival rate of treated mice were evaluated. Compared with the mice immunized with DNA vaccine (pcDNA/SAG1) encoding the same gene, BV-G-SAG1 induced higher levels of specific T. gondii antibody and (IFN)-gamma expression with dose-dependent manner and the survival rate of mice with BV-G-SAG1 was significantly improved. These results indicated that pseudotype baculovirus-mediated gene delivery can be utilized as an alternative strategy to develop new generation of vaccines against T. gondii infection.
 ...
PMID:Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. 2001 69

A pseudotype baculovirus with the glycoprotein of vesicular stomatitis virus (VSV-G) on the envelope was used as a vector for the construction of recombinant baculovirus expressing the G protein of rabies virus (RABV) under the cytomegalovirus (CMV) promoter. The generated recombinant baculovirus (BV-G) efficiently expressed the RABV G proteins in mammalian cells. Intramuscular vaccination with BV-G (10(9) PFU/mouse) induced the production of RABV G-specific neutralizing antibodies and strong T cell responses in mice. Our data clearly indicate that pseudotype baculovirus-mediated gene delivery can be utilized as an alternative strategy to develop a new generation of vaccine against RABV infection.
 ...
PMID:Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. 2122 73